Federal Register / Vol. 80, No. 76 / Tuesday, April 21, 2015 / Notices 22201 

5. Increase refugee knowledge of 

financial and monetary topics including 

developing a household budget; 

6. Assist refugees in advancing their 

education; 

7. Increase home ownership among 

refugees; and 

8. Assist refugees in gaining access to 

capital. 

The tools will collect information 

from grantees that will help ORR 

determine whether they are meeting the 

objectives of the program. Data to be 

collected will only include specialized, 

and relevant information to the program 

such as, number of people enrolled, 

amount in dollar allocated for matching 

IDA savings, number and value of assets 

purchased, confirmation of refugee 

status, and types and quantity of 

training provided. Tools will be used for 

semi-annual reports as well as for 

monitoring to ensure progress towards 

success, and appropriate use of federal 

funds. 

Respondents: Office of Refugee 

Resettlement Individual Development 

Accounts Program grantees. 

ANNUAL BURDEN ESTIMATES

Instrument Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden hours 

per response 

Total burden 

hours 

Program Status Report .................................................................................... 22 2 1 44 

Community Impact Report ............................................................................... 22 2 1 44 

Demographic .................................................................................................... 22 2 1 44 

Estimated Total Annual Burden 

Hours: 132 hours. 

Additional Information: Copies of the 

proposed collection may be obtained by 

writing to the Administration for 

Children and Families, Office of 

Planning, Research and Evaluation, 370 

L’Enfant Promenade SW., Washington, 

DC 20447, Attn: ACF Reports Clearance 

Officer. All requests should be 

identified by the title of the information 

collection. Email address: 

infocollection@acf.hhs.gov. 

OMB Comment: OMB is required to 

make a decision concerning the 

collection of information between 30 

and 60 days after publication of this 

document in the Federal Register. 

Therefore, a comment is best assured of 

having its full effect if OMB receives it 

within 30 days of publication. Written 

comments and recommendations for the 

proposed information collection should 

be sent directly to the following: Office 

of Management and Budget, Paperwork 

Reduction Project, Email: OIRA_

SUBMISSION@OMB.EOP.GOV, Attn: 

Desk Officer for the Administration for 

Children and Families. 

Robert Sargis, 

Reports Clearance Officer. 

[FR Doc. 2015–09192 Filed 4–20–15; 8:45 am] 

BILLING CODE 4184–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2015–N–0001] 

Request for Nominations on the 

Allergenic Products Advisory 

Committee 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is requesting that 

any industry organizations interested in 

participating in the selection of a 

nonvoting industry representative to 

serve on the Allergenic Products 

Advisory Committee for the Center for 

Biologics Evaluation and Research 

notify FDA in writing. FDA is also 

requesting nominations for a nonvoting 

industry representative to serve on the 

Allergenic Products Advisory 

Committee. A nominee may either be 

self-nominated or nominated by an 

organization to serve as a nonvoting 

industry representative. Nominations 

will be accepted for current or 

upcoming vacancies effective with this 

notice. 

DATES: Any industry organization 

interested in participating in the 

selection of an appropriate nonvoting 

member to represent industry interests 

must send a letter stating that interest to 

the FDA by May 21, 2015, (see sections 

I and II for further details). 

Concurrently, nomination materials for 

prospective candidates should be sent to 

FDA by May 21, 2015. 

ADDRESSES: All statements of interest 

from interested industry organizations 

interested in participating in the 

selection process of nonvoting industry 

representative nomination should be 

sent to Janie Kim (see FOR FURTHER

INFORMATION CONTACT). All nominations 

for nonvoting industry representatives 

may be submitted electronically by 

accessing the FDA Advisory Committee 

Membership Nomination Portal: 

https://www.accessdata.fda.gov/scripts/

FACTRSPortal/FACTRS/index.cfm or by 

mail to Advisory Committee Oversight 

and Management Staff, Food and Drug 

Administration, 10903 New Hampshire 

Ave., Bldg. 32, Rm. 5103, Silver Spring, 

MD 20993–0002. Information about 

becoming a member of an FDA advisory 

committee can also be obtained by 

visiting FDA’s Web site at http://

www.fda.gov/AdvisoryCommittees/

default.htm. 

FOR FURTHER INFORMATION CONTACT: 

Janie Kim, Center for Biologics 

Evaluation and Research, Food and 

Drug Administration, 10903 New 

Hampshire Ave., Silver Spring, MD 

20993, 301–796–9016, FAX: 301–595– 

1307, email: janie.kim@fda.hhs.gov. 

SUPPLEMENTARY INFORMATION: The 

Agency intends to add a nonvoting 

industry representative to the following 

advisory committee: 

I. Allergenic Products Advisory 

Committee 

The Committee reviews and evaluates 

available data concerning the safety, 

effectiveness, and adequacy of labeling 

of marketed and investigational 

allergenic biological products or 

materials that are administered to 

humans for the diagnosis, prevention, or 

treatment of allergies and allergic 

disease, and makes appropriate 

recommendations to the Commissioner 

of Food and Drugs of its findings 

regarding the affirmation or revocation 

of biological product licenses, on the 

safety, effectiveness, and labeling of the 

products, on clinical and laboratory 

studies of such products, on 

amendments or revisions to regulations 

governing the manufacture, testing and 

licensing of allergenic biological 

products, and on the quality and 

relevance of FDA’s research programs 

which provide the scientific support for 

regulating these agents. 


tkelley on DSK3SPTVN1PROD with NOTICES
22202 Federal Register / Vol. 80, No. 76 / Tuesday, April 21, 2015 / Notices 

II. Selection Procedure 

Any industry organization interested 

in participating in the selection of an 

appropriate nonvoting member to 

represent industry interests should send 

a letter stating that interest to the FDA 

contact (see FOR FURTHER INFORMATION

CONTACT) within 30 days of publication 

of this document (see DATES). Within the 

subsequent 30 days, FDA will send a 

letter to each organization that has 

expressed an interest, attaching a 

complete list of all such organizations; 

and a list of all nominees along with 

their current resumes. The letter will 

also state that it is the responsibility of 

the interested organizations to confer 

with one another and to select a 

candidate, within 60 days after the 

receipt of the FDA letter, to serve as the 

nonvoting member to represent industry 

interests for the committee. The 

interested organizations are not bound 

by the list of nominees in selecting a 

candidate. However, if no individual is 

selected within 60 days, the 

Commissioner will select the nonvoting 

member to represent industry interests. 

III. Application Procedure 

Individuals may self-nominate and/or 

an organization may nominate one or 

more individuals to serve as a nonvoting 

industry representative. Contact 

information, current curriculum vitae, 

and the name of the committee of 

interest should be sent to the FDA 

Advisory Committee Membership 

Nomination Portal (see ADDRESSES) 

within 30 days of publication of this 

document (see DATES). FDA will forward 

all nominations to the organizations 

expressing interest in participating in 

the selection process for the committee. 

(Persons who nominate themselves as 

nonvoting industry representatives will 

not participate in the selection process). 

FDA seeks to include the views of 

women, and men, members of all racial 

and ethnic groups and individuals with 

and without disabilities on its advisory 

committees and, therefore encourages 

nominations of appropriately qualified 

candidates from these groups. 

This notice is issued under the 

Federal Advisory Committee Act (5 

U.S.C. app. 2) and 21 CFR part 14, 

relating to advisory committees. 

Dated: April 15, 2015. 

Leslie Kux, 

Associate Commissioner for Policy. 

[FR Doc. 2015–09082 Filed 4–20–15; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2012–N–0386] 

Agency Information Collection 

Activities; Proposed Collection; 

Comment Request; Registration and 

Product Listing for Owners and 

Operators of Domestic Tobacco 

Product Establishments and Listing of 

Ingredients in Tobacco Products 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing an 

opportunity for public comment on the 

proposed collection of certain 

information by the Agency. Under the 

Paperwork Reduction Act of 1995 (the 

PRA), Federal Agencies are required to 

publish notice in the Federal Register 

concerning each proposed collection of 

information including each proposed 

extension of an existing collection of 

information, and to allow 60 days for 

public comment in response to the 

notice. This notice solicits comments on 

the proposed extension of an existing 

collection of information pertaining to 

registration and product listing for 

owners and operators of domestic 

tobacco product establishments and 

listing of ingredients in tobacco 

products. 

DATES: Submit either electronic or 

written comments on the collection of 

information by June 22, 2015. 

ADDRESSES: Submit electronic 

comments on the collection of 

information to http://

www.regulations.gov. Submit written 

comments on the collection of 

information to the Division of Dockets 

Management (HFA–305), Food and Drug 

Administration, 5630 Fishers Lane, Rm. 

1061, Rockville, MD 20852. All 

comments should be identified with the 

docket number found in brackets in the 

heading of this document. 

FOR FURTHER INFORMATION CONTACT: FDA 

PRA Staff, Office of Operations, Food 

and Drug Administration, 8455 

Colesville Rd., COLE–14526, Silver 

Spring, MD 20993–0002, PRAStaff@

fda.hhs.gov. 

SUPPLEMENTARY INFORMATION: Under the 

PRA (44 U.S.C. 3501–3520), Federal 

Agencies must obtain approval from the 

Office of Management and Budget 

(OMB) for each collection of 

information they conduct or sponsor. 

‘‘Collection of information’’ is defined 

in 44 U.S.C. 3502(3) and 5 CFR 

1320.3(c) and includes Agency requests 

or requirements that members of the 

public submit reports, keep records, or 

provide information to a third party. 

Section 3506(c)(2)(A) of the PRA (44 

U.S.C. 3506(c)(2)(A)) requires Federal 

Agencies to provide a 60-day notice in 

the Federal Register concerning each 

proposed collection of information, 

including each proposed extension of an 

existing collection of information, 

before submitting the collection to OMB 

for approval. To comply with this 

requirement, FDA is publishing notice 

of the proposed collection of 

information set forth in this document. 

With respect to the following 

collection of information, FDA invites 

comments on these topics: (1) Whether 

the proposed collection of information 

is necessary for the proper performance 

of FDA’s functions, including whether 

the information will have practical 

utility; (2) the accuracy of FDA’s 

estimate of the burden of the proposed 

collection of information, including the 

validity of the methodology and 

assumptions used; (3) ways to enhance 

the quality, utility, and clarity of the 

information to be collected; and (4) 

ways to minimize the burden of the 

collection of information on 

respondents, including through the use 

of automated collection techniques, 

when appropriate, and other forms of 

information technology. 

Registration and Product Listing for 

Owners and Operators of Domestic 

Tobacco Product Establishments and 

Listing of Ingredients in Tobacco 

Products (OMB Control Number 0910– 

0650)—Extension) 

On June 22, 2009, the President 

signed the Tobacco Control Act (Pub. L. 

111–31) into law. The Tobacco Control 

Act amended the Federal Food, Drug, 

and Cosmetic Act (the FD&C Act) (21 

U.S.C. 301) by, among other things, 

adding a chapter granting FDA 

important authority to regulate the 

manufacture, marketing, and 

distribution of tobacco products to 

protect the public health generally and 

to reduce tobacco use by minors. 

Section 905(b) of the FD&C Act (21 

U.S.C. 387e(b)), as amended by the 

Tobacco Control Act, requires that every 

person who owns or operates any 

establishment in any State engaged in 

the manufacture, preparation, 

compounding, or processing of a 

tobacco product or tobacco products 

register with FDA the name, places of 

business, and all establishments owned 

or operated by that person. Every person 

must register by December 31 of each 

year. Section 905(c) of the FD&C Act 

requires that first-time persons engaging 


tkelley on DSK3SPTVN1PROD with NOTICES